Historical record - last NADAC effective date: 4/17/2024
Product Information
ERYPED 200 MG/5 ML SUSPENSION is a brand product labeled by Azurity Pharmaceuticals Inc., priced at $3.6046 per ML under NDC 24338013213. Its NADAC has been published 404 times since Nov 28, 2013.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/5mL
Manufacturer
Azurity Pharmaceuticals Inc.NDC
24338013213
Classification
Brand
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
4/17/2024
Active Ingredients
ERYTHROMYCIN ETHYLSUCCINATEApproval Type
New Drug (NDA)
FDA Application
NDA050207FDA Approved
Before 1982
TE Code
AB
On Market Since
7/5/2011
Pharmacological Classes
Price Statistics
The NADAC for ERYPED 200 MG/5 ML SUSPENSION has been published 404 times since Nov 28, 2013, and over the history we have for it it has risen 166.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.6046 per ML |
|---|---|
| All-time high | $3.6452 (Oct 11, 2017) |
| All-time low | $1.3519 (Nov 28, 2013) |
| Median price | $3.6046 |
| Average price | $3.2719 |
| Largest weekly change | +30.0% (Mar 5, 2014) |
| Weeks tracked | 404 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-0.1%
5Y
-0.1%
All
+166.6%
Last surveyed Apr 16, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 75% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Azurity Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Erythromycin Ethylsuccinate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Macrolide Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ERYPED 200 MG/5 ML SUSPENSION?
The current National Average Drug Acquisition Cost (NADAC) for ERYPED 200 MG/5 ML SUSPENSION, manufactured by Azurity Pharmaceuticals Inc., is $3.6046 per ML (NDC 24338013213), effective Apr 16, 2025.
How has the price of ERYPED 200 MG/5 ML SUSPENSION changed over time?
Over the history we have for it, the NADAC for ERYPED 200 MG/5 ML SUSPENSION has risen 166.6%. It has been tracked across 404 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ERYPED 200 MG/5 ML SUSPENSION?
Since Nov 28, 2013, the NADAC for ERYPED 200 MG/5 ML SUSPENSION has ranged from a low of $1.3519 (Nov 28, 2013) to a high of $3.6452 (Oct 11, 2017), with a median of $3.6046 per ML.
Are there cheaper alternatives to ERYPED 200 MG/5 ML SUSPENSION?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ERYTHROMYCIN 200 MG/5 ML SUSP, is $0.9123 per ML — about 75% below ERYPED 200 MG/5 ML SUSPENSION.
Who manufactures ERYPED 200 MG/5 ML SUSPENSION?
ERYPED 200 MG/5 ML SUSPENSION (NDC 24338013213) is labeled by Azurity Pharmaceuticals Inc., and CMS classifies it as a brand product.